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List of abbreviations 
 
ALT: alanine aminotransferase 
AST: aspartate aminotransferase 
BMI: body mass index 
BUDAPEST-GLOBAL: Burden of atherosclerotic plaques study in twins - Genetic      
Loci and the Burden of Atherosclerotic Lesions 
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CRP: C-reactive protein 
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DCCT/EDIC: Diabetes Control and Complications Trial / Epidemiology of Diabetes 
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HDL-cholesterol: high-density lipoprotein cholesterol 
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ICC: intra-class correlation coefficient 
IL-1β: interleukin-1β 
IL-6: interleukin-6 
JNK: Jun N-terminal kinase 
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MCP-1: monocyte chemoattractant protein-1 
MDCT: multidetector-row CT 
MESA: Multiethnic Study of Atherosclerosis 
MRI: magnetic resonance imaging 
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NAFLD: non-alcoholic fatty liver disease 
NASH: non-alcoholic steatohepatitis 
NFkappaB: nuclear factor-kappa-B 
NSTEMI: non-ST-elevation myocardial infarction 
OR: odds ratio 
PAI-1: plasminogen activator inhibitor-1 
ROI: region of interest 
SAT: subcutaneous adipose tissue 
SD: standard deviation 
SPECT: single photon emission computed tomography 
TIMI: thrombolysis in myocardial infarction 
TNF-α: tumor necrosis factor-α 
UCP-1: uncoupled protein-1 







1.1. Epicardial adipose tissue 
 
Type 2 diabetes mellitus and its cardiovascular complications carry a great burden for the 
health care system worldwide due to their high prevalence rate (1). Insulin resistance 
syndrome with the dysfunction of abdominal fat compartment plays an important role in 
the development of the disease (2, 3). In the last couple of years it was demonstrated that 
other fat compartments may also be involved in the insulin resistance syndrome and may 
contribute to the pathogenesis of atherosclerosis (4). Recently, the epicardial fat 
compartment has gained special attention in this regard (5-7).  
 
In the 19th century it was believed that fatty degeneration of the heart is the main cause 
of every heart disease (8). Richard Quain was the most well-known scientist supporting 
this theory recognizing the relationship of increased fat volume on the epicardial surface 
with coronary artery obstruction. The diagnosis of fatty heart was very popular in the 
Victorian era but was later changed to the concept of fibrosus heart disease and chronic 
myocarditis. All these diagnoses were replaced by the ischemia-theory in the middle of 
the 20th century. Interestingly, it was recognized at that time that in 70% of the fatty heart 
diagnosis in Quain’s pathological records corresponded with the ischemic heart disease. 
Although the relationship between increased epicardial fat quantity and different cardiac 
pathologies was described almost 150 years ago, medicine did not dedicate to much 
attention to this field. Cardiovascular research has begun to explore the role of different 
fat compartments with the pandemic spread of obesity and the dynamic development of 
radiological imaging technics (9). Lately, special attention was paid to the epicardial fat 
due to its anatomical proximity with the coronary arteries (10-12). While anatomical and 
biochemical characteristics of the epicardial fat compartment were described in early 
studies, its potential role in the pathomechanism of coronary artery disease (CAD) and 








The exact terminology of fat compartments covering and surrounding the heart is not 
standardized; there are still many imprecise uses of these definitions in the literature. 
Nevertheless, the most widely used and accepted terms are summarized in Table 1.  
 
Table 1. Terminology of fat compartments around the heart  
Visceral fat Adipose tissue around the visceral organs 
Epicardial fat Visceral fat between the myocardial 
surface and the visceral layer of the 
pericardium 
Pericardial fat Adipose tissue between the two 
pericardial layers (visceral and parietal 
pericardium) and fat depot on the external 
surface of the parietal pericardium 
Paracardial fat Fat deposits outside the parietal 
pericardium (extra-pericardial thoracic 
fat) 
Perivascular (pericoronary) fat Adipose tissue around the vessels 
(coronary arteries) irrespective of location 
Ectopic fat Lipid (triglycerides) deposits in non-




The epicardial fat as a part of the visceral fat is localized between the myocardial surface 
and the visceral layer of the pericardium. Pericardial fat involves adipose tissues between 
the two (visceral and parietal) pericardial layers and the fat depot on the external surface 
of the parietal pericardium. Paracardial fat contains fat deposits outside the parietal 
pericardium and therefore, sometimes is called as extra-pericardial intrathoracic fat. The 




location. The term of ectopic fat implies triglycerides deposits in non-adipose tissue of 
different organs such as myocardium, muscle, liver, or pancreas (13). 
 
The clear distinction of epicardial fat from pericardial fat is of great clinical importance 
(14, 15). From embryological aspect they have different origins. While the epicardial fat 
- similarly to the visceral fat - originates from mesodermal cells, the pericardial fat has an 
ectodermal origin, similarly to subcutaneous fat. Moreover, there is also a difference in 
the blood supply between these two fat compartments. Epicardial fat is supplied by the 
small myocardial coronary arteries, on the other hand, the blood supply of pericardial fat 
is provided from the thoracic vessels. The amount of epicardial and pericardial fat 
compartments as percentage of total cardiac mass also differs (Table 2).  
 
 
Table 2. Differences between epicardial and pericardial fat compartments 
 Epicardial fat  Pericardial fat 
Location between the myocardial 
surface and the visceral 
pericardium 
 outside the visceral 
pericardium, between the 
visceral and parietal 
pericardium and on the 
external surface of the 
parietal pericardium 
Embryologic origin splanchnopleuric 
mesoderm 
 primitive thoracic 
mesenchyme 
Blood supply branches form the coronary 
arteries 
 non-coronary sources 
(branches from the internal 
mammary artery) 








1.1.2. Imaging of epicardial adipose tissue 
 
The most commonly used non-invasive modalities for the visualization and quantification 
of epicardial fat tissue are echocardiography, magnetic resonance imaging (MRI) and 
cardiac computed tomography (CT).  
 
Echocardiography provides a simple, cheap and readily available assessment which 
pictures directly the epicardial adipose tissue (EAT) thickness on the free wall of the right 
ventricle. Importantly, this technique does not subject the patient to ionizing radiation. 
Echocardiographic assessment of EAT thickness requires parasternal short- and long-axis 
views in three following end-systolic phases (Figure 1). Several studies have established 
the general EAT thickness under 7 mm in asymptomatic population (16). Nevertheless, 
this method has several disadvantages including the poor reproducibility and the high 
dependence on the observer’s experience. In addition, it may not reflect accurately the 
whole quantity of the epicardial fat due to the two-dimensional nature of the 
measurement. Moreover, the method has poor intra- and interobserver variability, and its 






Figure 1.  
Quantification of epicardial adipose tissue by echocardiography (parasternal view). The 
thickness of the area between the myocardium and the visceral layer of the pericardium 
is 0.85 cm indicating epicardial adipose tissue (E, green arrow). 
 
 
In contrast to echocardiography, MRI provides accurate area measurements and, in this 
way, EAT volume can be calculated (Figure 2). Area measurements with MRI 
correspond well with fat thickness determination with echocardiography, although a 
systemic bias through overestimation of EAT with echocardiography might occur (19). 
Although the lack of ionizing radiation is preferable, there are disadvantages of this 
modality; it is less available in routine clinical practice, it is more expensive and has worse 







Epicardial adipose tissue (green arrow) demonstrated using magnetic resonance imaging 
(MRI) technique. 
RA: right atrium, LA: left atrium, RV: right ventricle, LV: left ventricle 
 
 
True volume assessment of EAT is feasible using multidetector-row CT (MDCT), which 
has superior spatial resolution among the imaging modalities (Figure 3). It is of note that 
the specificity and sensitivity of epicardial fat measurements with MDCT are the best 
comparing to alternative imaging methods. Epicardial fat quantification is performed in 
a standardized fashion on prospectively ECG triggered non-contrast CT scans which 
extend from the pulmonary artery bifurcation to the diaphragm. The identification of EAT 
is based on thresholds of fat attenuation. Typically, lower thresholds of attenuation range 
from -250 to -190 Hounsfield units (HU) and upper thresholds are set between -50 and  
-30 HU. In contrast to area and thickness measurements, volume quantification provides 
the most accurate way for assessing the true epicardial fat quantity which can be 
performed on volume rendered image reconstructions (20). In addition, non-enhanced 




resulting in more reliable cardiovascular risk assessment (21). Importantly, native CT 
results in a very small (~0.5 mSv) radiation dose. Maurovich-Horvat et al found in a 
former collaborative work that the measurement of pericoronary adipose tissue proved to 




Measuring epicardial adipose tissue quantity by cardiac computed tomography (CT)  
a) Axial section at the aortic root. The green arrows indicate the visceral layer of the 
pericardium. Epicardial fat (E) is located inside while pericardial fat (P) outside 
of the visceral layer. 
b) Epicardial adipose tissue (yellow) at the corresponding section 
c) Volume rendered reconstruction of the total epicardial fat compartment (yellow). 
The volume of epicardial adipose tissue was 112 cm3. 
 
 
1.1.3. Anatomical characteristics of EAT 
 
In physiological circumstances the epicardial fat covers nearly 80% of the heart surface. 
According to earlier observations this fat compartment contributes with 20% to the whole 
heart quantity (23). The EAT-covered heart region includes the heart basis and the apex, 
the atrioventricular sulci, the entire surface of the right ventricle, and the great coronary 
vessels with their origins. The distribution of EAT is mostly inhomogeneous, the biggest 
mass is localized on the lateral and anterior walls of the right atrium, but in normal 




main coronary arteries as well. In case of extremely enlarged EAT, it can accumulate also 
on the surface of the left atrium and along the vessel’s adventitia with spreading into the 
myocardium. It is of note, that there is no separating fascia layer between the epicardial 
fat and the myocardium providing a close proximity of these two different tissues (24). 
In histological investigations it has been earlier established that adipocytes in the EAT 
are smaller than those in the abdominal or the subcutaneous fat compartments (25). 
Beyond adipocytes, EAT includes nerves, ganglions, vessels, inflammatory cells and 
fibrocytes as well (Figure 4). 
 
 
Figure 4.  
Microscopic view of the epicardial adipose tissue. It is of note that there is no separating 
fascia layer between the epicardial fat and the myocardium.  
(Histological image is courtesy of Zoltán Sápi, MD, DSc, Semmelweis University, 




Age, gender, body weight and ethnicity should be taken into consideration among 
physiological determinants of EAT (26-29). EAT seems to increase with age (30). The 
quantity of EAT depends on gender and body mass index (BMI). For example, pericardial 
fat was reported to be 137±54 cm3 among men and 108±41 cm3 among women of the 
Framingham offspring cohort (31). In patients with high BMI (>27 kg/m2) EAT volume 
was more than two times higher compared to those with a BMI <27 kg/m2 (155±15 cm3 
vs 67±12 cm3) (20). Some ethnic differences in epicardial and pericardial fat thickness 
may also occur; non-Hispanic White men have more epicardial and pericardial fat than 
do African Americans (32). 
 
The biochemical features of small adipocytes in EAT may also differ from those of other 
fat compartments. In experimental studies EAT had higher rate of free fatty acid (FFA) 
release than adipose tissue elsewhere in the body suggesting that EAT might play a role 
in local energy supply for the myocardium. In addition, a lower oxidative capacity and a 
lower rate of glucose utilization were also documented (33). On the other hand, a 5-fold 
higher expression of uncoupled protein-1 (UCP-1) was found in EAT comparing to other 
fat depots (34). The UCP-1 is a specific protein in brown fat which is necessary to its 
energy production, and doesn’t appear in other type of fat tissues. This latter feature is in 




1.1.4. Physiological function of EAT 
 
Several physiological functions of EAT are already known from different studies or 
supposed from its biochemical or anatomical features. Unfortunately, experimental 
evidences supporting these observations are limited due to the very small amount of EAT 
in experimental animals (rodents).  
 
It is suggested that functions of EAT may include protection of the myocardium against 
hypothermia (34). In addition, EAT can provide a mechanical protective role for coronary 




arterial pulse wave but it has a permissive role as well in positive remodeling of coronary 
arteries (35).  
 
Besides this, EAT has a substantial role in energy supply to the myocardium and should 
be considered as a provider of energy source during period of high energy demand (13). 
On the other hand, EAT may protect the myocardium from cardiotoxic effect of large 
amount of FFA due to its capacity of fast FFA utilization (36). Taken together EAT may 
serve as a unique energy buffering pool in the homeostasis of the myocardium. 
 
In addition, adiponectin secretion from epicardial adipocytes may promote the coronary 
circulation. Adiponectin improves the endothelial function through stimulation of the 
nitrogen monoxide synthase, reduces the oxidative stress, and indirectly decreases the 
level of interleukin-6 (IL-6) and C-reactive protein (CRP) by reducing tumor necrosis 
factor-α (TNFα) production (37, 38). Adiponectin also has some extracardiac effect such 
as increased glucose utilization in the hepatocytes and muscle cells which may result in 
improving insulin sensitivity (39).  
 
 
1.1.5. EAT in the pathomechanism of atherosclerosis  
 
Some years ago a hypothesis about the direct role of EAT in the development and 
progression of coronary atherosclerosis has been raised and paracrine and vasocrine 
effects of EAT due to close proximity of epicardial fat to coronary arteries were supposed 
(40). The hypothesis was indirectly supported by a pathological study in subjects with 
myocardial bridge. Namely, no atherosclerosis was observed in coronary segments at 
myocardial bridge where surrounding fat on the coronary arteries was lacking (41).  
 
In a landmark study, Mazurek et al analyzed epicardial and subcutaneous fat from the 
lower extremity in obese patients referred for coronary artery bypass grafting. They found 
increased level of inflammatory mediators (IL-6, TNF-α, interleukin-1β [IL-1β], 
monocyte chemoattractant protein-1 [MCP-1]), macrophages, lymphocytes and basophils 




epicardial and omental fat exhibited a broadly comparable pathogenic messenger 
ribonucleotide acid (mRNA) profile indicating macrophage infiltration into the epicardial 
fat (43). In another study, mediators of the nuclear factor-kappaB (NFkappaB) and c-Jun 
N-terminal kinase (JNK) pathways were suggested to involve in the inflammatory profile 
of EAT highlighting the role of the macrophages in the inflammation within this tissue 
(44). These studies indicate that chronic inflammation occurs locally as well as 
systemically potentially contributing further to the pathogenesis of CAD.  
 
It was documented that the epicardial adipocytes had impaired adiponectin secretion and 
increased leptin production in obese patients with hypertension, metabolic syndrome and 
CAD (45, 46). This shift in the adiponectin/leptin ratio enhances the development of 
atherosclerosis. Namely, the decreased adiponectin expression attenuates endothelial 
function and leads to increased TNF-α production triggering systematic inflammation and 
oxidative stress. The altered leptin level promotes atherogenic changes in endothelial 
cells such as increased adhesion of monocytes, higher level of macrophage-to-foam cell 
transformation, unfavorable changes in lipid levels, and elevation of CRP and 
inflammatory cytokine levels. All these alterations may lead to development and 
destabilization of atherosclerotic plaques in coronary arteries (5). 
 
Based on several studies it became widely accepted that EAT should be considered as a 
source of inflammatory mediators that might directly influence the myocardium and 
coronary arteries (Figure 5) (47, 48). Two mechanisms of influence (paracrine and 
vasocrine) were suggested (40). Paracrine way of influence means that adipokines 
released from pericoronary fat may diffuse across the arterial wall (adventitia, media, and 
intima) and finally can interact with endothelial cells in the intima and with vascular 
smooth cells in the media. The alternative vasocrine way of effect can be realized by 
release of adipocytokines and FFAs from EAT directly into vasa vasorum of the coronary 
arterial wall (49). It was suggested that vasocrine way of influence may be predominant 
over paracrine effect in case of more advanced atherosclerotic lesions where 







Routes for paracrine and vasocrine effects of epicardial adipose tissue on coronary 
arteries and plaque formation. 
IL: interleukin, TNF-α: tumor necrosis factor-α, MCP-1: monocyte chemoattractant 




The relationship of EAT with CAD were analyzed by several clinical studies (50-55). In 
the Framingham and the MESA (Multiethnic Study of Atherosclerosis) epidemiological 
studies a significant association of epicardial fat with coronary artery calcification was 
found which remained significant after adjustment for traditional cardiovascular risk 
factors (56, 57). The increased epicardial fat proved to be associated with more advanced 
atherosclerosis in another study (58). Epicardial fat was associated with non-calcified 
coronary plaques as well (59, 60). A significant relationship of increased epicardial fat 
volume (>130.7 cm3) with vulnerable plaques was also documented (61). The relationship 




calcifications, and low CT attenuation in necrotic core) to the pericardial fat was also 
studied and the volume of pericardial fat proved to be nearly twice as high in patients 
with vulnerable plaques as compared to those without CAD (62, 63). Pericardial fat was 
associated with myocardial ischemia detected by single photon emission computed 
tomography (SPECT) in patients without known CAD (64). EAT correlated with the 
degree of coronary atheromatosis suggesting that its excessive accumulation might 
contribute to the development of acute coronary syndrome and coronary total occlusions 
(65, 66). In another study, EAT thickness was independently associated with the 
thrombolysis in myocardial infarction (TIMI) risk score in patients with non-ST-elevation 
myocardial infarction (NSTEMI) and unstable angina pectoris (67). In patients with the 
metabolic syndrome increased EAT was associated with impaired coronary flow reserve 
(68). In a different patient population (in women with chest pain and angiographically 
normal coronary arteries) EAT thickness was correlated with reduced coronary flow 
reserve (69). Different surrogate parameters of atherosclerosis were also investigated by 
others and an association between EAT thickness and carotid intima-media thickness in 
type 2 diabetic patients as well as in children and adolescents with obesity was found (70, 
71). Moreover, EAT showed an independent association with arterial stiffness in an 
asymptomatic Korean cohort (72). In a recent study, Maurovich-Horvat et al investigated 
the relationship of different thoracic fat depots with coronary atherosclerosis and found 
an independent association between pericoronary fat and CAD. In addition, pericoronary 
fat correlated with inflammatory biomarkers as well suggesting that while systemic 
inflammation plays a role in the pathogenesis of CAD, there are additional local effects 
that may exist (73). In a systematic review and meta-analysis an association between the 
elevated location-specific thickness of EAT at the left atrioventricular groove and the 
obstructive CAD was found (55). 
 
In the majority of studies increase of EAT volume was associated with stenosis of the 
coronary arteries (74, 75). Since these studies are cross-sectional it is uncertain whether 
adipose tissue plays a causal role in the development of atherosclerosis. Importantly, two 
longitudinal studies have reported results that support the hypothesis of ‘outside to inside 
signaling’ as a cause of atherosclerosis (56, 76). In these studies, intrathoracic fat and 




incident coronary heart disease and with major adverse cardiac events. Associations were 
independent from BMI and other risk factors, suggesting that EAT is one of the factors 
contributing to CAD. 
 
 
1.1.6. Role of EAT in other cardiac and non-cardiac abnormalities 
 
The relationship of EAT with atrial fibrillation was analyzed in several clinical studies 
(77-79). A strong association between EAT and atrial fibrillation (both paroxysmal and 
persistent) was documented by Al Chekakie et al; the relationship proved to be 
independent of traditional risk factors and atrial enlargement (80). In another study, EAT 
thickness was verified as an independent predictor for post-ablational recurrence of atrial 
fibrillation (81). In patients with peritoneal dialysis the increased EAT was associated 
with impaired left ventricle diastolic capacity independently of CRP level, a marker of 
systemic inflammation (82). 
 
Epicardial fat necrosis is a rare clinical condition, 26 cases were reported till 2011 (83). 
It should be considered among differential diagnoses of chest pain. The etiology is 
obscure, but the prognosis is good. In general, the presenting symptom is left-sided chest 
pain in a previously healthy individual with an associated juxtacardiac mass seen in chest 
radiography. CT or MRI may confirm the correct diagnosis resulting in the avoidance of 
surgical intervention. 
 
Typically, type 2 diabetes is preceded by prediabetes but insulin resistance syndrome due 
to obesity may be the first pathological stage in the long-lasting asymptomatic period of 
diabetes. The insulin resistance syndrome (called also as the metabolic syndrome) 
includes insulin resistance and different metabolic abnormalities (elevated serum 
triglycerides, lower HDL-cholesterol, hyperglycemia) as well as elevated blood pressure. 
Obesity, especially abdominal visceral fat accumulation plays a central role in this 
syndrome. Although the use of term and the suggested pathomechanism of the metabolic 




abdominal visceral fat compartment and the increased cardiovascular risk remained 
unquestionable (84).  
Several clinical investigations were dedicated to assess the characteristics of EAT in the 
metabolic syndrome, prediabetes and type 2 diabetes. In a meta-analysis, EAT was 7.5 ± 
0.1 mm in thickness in the metabolic syndrome (n=427) compared to 4.0 ± 0.1 mm in 
controls (n=301) and EAT correlated significantly with the components of the metabolic 
syndrome (85). EAT volume was significantly higher in patients with type 2 diabetes than 
in nondiabetic subjects and EAT volume was significantly associated with components 
of the metabolic syndrome (58). In asymptomatic type 2 diabetic patients the thickness 
of EAT proved to be an independent risk factor for significant coronary artery stenosis 
but not for silent myocardial ischemia (86). A strong correlation was found between 
fasting plasma glucose and EAT measured with CT or echocardiography (87, 88). EAT 
quantity was higher in patients with type 2 diabetes mellitus compared to lean subjects or 
obese patients without diabetes. In addition, the difference in EAT volume between men 
and women was more pronounced in subjects with impaired fasting glucose or diabetes 
mellitus (89). A clear relationship of epicardial fat and serum alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) activity, surrogate markers of fatty liver, 
were documented in a cross-sectional, observational study (90). Taken together, the 
insulin resistance syndrome (the metabolic syndrome), type 2 diabetes, non-alcoholic 
fatty liver disease (NAFLD) and CAD are associated with increased amount of epicardial 
fat (91). 
 
The role of EAT was also investigated in type 1 diabetes. Interestingly, higher epicardial 
fat and serum leptin levels were found in subjects with type 1 diabetes than in non-
diabetic controls. The epicardial fat thickness and serum leptin levels proved to be the 
best independent correlates of each other in patients with type 1 diabetes independently 
of BMI, glycemic control and daily insulin requirement (92). Recently, patients with type 
1 diabetes (n=100) from the Diabetes Control and Complications Trial / Epidemiology of 
Diabetes Interventions and Complications (DCCT/EDIC) study were investigated. In this 
pilot study, the accumulation of adipose tissue in epicardial and intra-thoracic spaces 




greater weighted glycated hemoglobin values, elevated triglycerides and a history of 
elevated albumin excretion rate or end-stage renal disease (93).  
 
 
1.1.7. Treatment options for modifying EAT volume 
 
Lifestyle changes, bariatric surgery and different drugs may apply. Reduction in weight 
(BMI) by using very-low calorie diet resulted in a decrease of EAT volume in severely 
obese subjects (n=20; echocardiographic EAT thickness at baseline: 12.3±1.8 mm, at 6 
months follow-up: 8.3±1.0 mm; p=0.001) (94). Similarly, beneficial effect was observed 
as a result of regular exercise training in a small group of patients (n=24; 
echocardiographic EAT volume at baseline: 8.11±1.64 mm, at 12 weeks follow-up: 
7.39±1.54; p<0.001) (95). In addition, EAT volume decreased after bariatric surgery as 
well, however one study found that myocardial triglyceride content did not change 
significantly (96, 97). In a meta-analysis, diet or bariatric surgery proved to be more 
beneficial than exercise training in reducing EAT volume (98). The effect of drugs on 
EAT is controversial (99-101). Atorvastatin resulted in a more pronounced decrease of 
EAT than simvastatin/ezetimibe (102). Pioglitazone compared with metformin increased 
pericardial fat volume in patients with type 2 diabetes (103). Short term (3 months) use 
of glucagon-like-receptor agonists (exenatide, liraglutide) decreased the volume of EAT 
in type 2 diabetic patients (104). In a longer (26 weeks) randomized controlled trial 
exenatide twice daily (versus standard antidiabetic treatment) proved to be effective in 
reducing both epicardial and liver fat content in obese patients with type 2 diabetes 
(n=44). In this study EAT volume was measured by MRI and expressed as ml; the initial 
EAT value changed by -8.8±2.1% in the exenatide group whereas minimal change was 
observed in patients with standard treatment (-1.2±1.6%; p=0.0003). The beneficial effect 
was mainly weight loss dependent (105). In another pilot study, sitagliptin, a dipeptidyl-
peptidase-4-inhibitor, also decreased the volume of EAT in a 24-week long study with 
obese type 2 diabetic patients (n=26); echocardiographic EAT thickness decreased from 
9.98±2.63 mm to 8.10±2.11 mm; p<0.001) (106). Lately, SGLT2-inhibitors are emerging 
as potential new therapeutic options as multiple studies reported a significant decrease in 




documented that EAT volume (measured by CT) significantly decreased by the end of 6 
months follow-up in type 2 diabetic patients (n=40) with dapagliflozin treatment vs. 
conventional antidiabetic therapy (-16.4±8.3 cm3 vs. 4.7±8.8 cm3; p=0.01). Clearly, EAT 
should be considered as a novel therapeutic target and statins, as well as antidiabetic drugs 
are the best candidates so far (110, 111).  
 
 
1.2. Relationship of EAT to other fat compartments 
 
Association between EAT and other fat compartments was investigated by several 
authors and was a topic of a recent position statement (57, 112, 113). Generally, EAT 
volume and obesity parameters (weight, BMI and waist circumference) are closely related 
(85, 114). Nevertheless, the clinical significance of abdominal subcutaneous adipose 
tissue (SAT) and visceral adipose tissue (VAT) differ. While abdominal SAT should be 
considered as a manifestation of enlarged fat depot, abdominal VAT is involved in the 
pathomechanism of the metabolic syndrome and may increase the cardiovascular risk 
through production of different cytokines (4). Particular abdominal fat depots carry 
specific clinical consequences. The enlarged visceral fat depot is characterized primarily 
with increased lipolysis leading to hepatic steatosis. Non-alcoholic fatty liver disease is 
often regarded as the hepatic manifestation of the insulin resistance (115) and is 
considered as a novel predictor of cardiovascular disease (116, 117). Importantly, 
NAFLD may progress from steatosis to non-alcoholic steatohepatitis (NASH) and even 
to cirrhosis and liver cancer (118). There are some publications indicating that EAT 
volume is associated with increasing hepatic lipid accumulation (119). Interestingly, fat 
deposition in the pancreas (fatty pancreas), termed non-alcoholic fatty pancreas disease 
(NAFPD) has gained much attention only in the last years (120). Lipid accumulation in 
pancreas may promote the development of chronic pancreatitis and exacerbate the clinical 
picture of acute pancreatitis (121). The potential relationship of pancreatic lipid 
accumulation with β-cell dysfunction is debated (122). NAFLD may often coexist with 






1.3. Contribution of genetic and environmental factors on fat 
compartments 
 
As fat compartments differ in embryogenetic origin, physiological and 
pathophysiological functions (124) it is plausible that their accumulation leads to local or 
systemic adiposity and increase of their quantity is influenced by genetic and 
environmental factors. Classical twin studies compare monozygotic (MZ) and dizygotic 
(DZ) same-gender twin pairs to help evaluate the degree of genetic and environmental 
influences on body composition (125).  
 
As for obesity (BMI) in general, earlier studies demonstrated a predominant genetic effect 
on BMI. It seems that anthropometric parameters (weight, height and, consequently BMI) 
are highly dependent on genetics. In a clinical study with twins from Hungary, phenotype 
of weight proved to be dependent on genetic factors by 88% (126). An international twin 
study documented that heritability contributed by 82% for weight and by 79% for BMI 
phenotypes (127). In a twin study from the United States, 63.6% of the total variance of 
BMI was explained by genetic components (128). In a review paper, authors reported 
heritability estimates of BMI between 0.57 and 0.86 in twins from early adulthood to late 
middle age (129). 
 
As for abdominal obesity (waist circumference), genetic and environmental influences 
were also investigated, and authors found in an earlier study performed by dual-energy 
x-ray absorptiometry that genetics highly predominated over environmental factors in 
contribution to phenotype (130). In the already mentioned Hungarian twin study 
heritability for waist circumference was calculated as high as 71% (126). This number 
was 74% in the international twin study (127). 
 
Abdominal SAT and VAT quantities were evaluated in the Framingham Heart Study 
Offspring and Third-Generation Study cohorts. It has been shown by CT imaging that 
abdominal SAT and VAT quantities have a heritability of 57% and 36%, respectively 
(131). However, the methodology for evaluating heritability in this study differed from 




Intraabdominal adipose tissue compartments were investigated in early family studies as 
well, where estimates for VAT ranged between 42% and 56% whereas that of SAT 
proved to be 42% (132, 133). Taken together, data regarding the heritability of abdominal 
adipose tissue compartment sizes are scarce and the findings are based on family studies 
and on measurement methods with limited accuracy.  
 
Regarding EAT, we did not find former data available whether EAT compartment 
quantity depends predominantly on genetic or environmental factors.  
 
 
1.4. Summarizing data from the literature 
 
The epicardial fat is a unique fat compartment localized between the myocardial surface 
and the visceral layer of the pericardium. The EAT can be quantified by non-invasive 
cardiac imaging techniques such as echocardiography, MRI or cardiac CT.  
 
Among physiological determinants of EAT age, gender, body weight and ethnicity should 
be considered. Physiological functions of EAT may include protection of the myocardium 
against hypothermia and a mechanical protective role for coronary circulation. In 
addition, EAT may serve as a unique energy buffering pool in the homeostasis of the 
myocardium.  
 
As for pathophysiological functions it is widely accepted that EAT should be considered 
as a source of inflammatory mediators that might directly influence the myocardium and 
coronary arteries. In line with these observations clinical studies suggested that EAT - 
through paracrine and vasocrine effects - may have an impact on the development and 
progression of coronary atherosclerosis. In addition, an association between increased 
EAT and atrial fibrillation was also documented. The insulin resistance syndrome (the 
metabolic syndrome), type 2 diabetes, NAFLD and CAD proved to be associated with 
increased amount of epicardial fat. Interestingly, an accumulation of EAT was observed 





Treatment options for modifying EAT volume include lifestyle changes, bariatric surgery 
and using different drugs. Weight reduction in obese subjects may lead to a decrease in 
EAT volume while effects of different drugs on EAT are controversial. Nevertheless, 
EAT should be considered as a new cardiovascular therapeutic target. 
 
No data are available whether EAT compartment quantity depends predominantly on 
genetic or environmental factors. Furthermore, data regarding the heritability of 
abdominal adipose tissue compartment sizes are scarce and the findings are based on 




2. Aims     
 
After adopting a proper and reliable method for evaluating the quantity of EAT by using 
cardiac CT scan in our department, we designed a study to evaluate the heritability of 
EAT quantity in comparison to that of abdominal SAT and VAT volumes. Then, we 
assessed the association between EAT volume and the presence of CAD in order to 
evaluate to potential role of EAT in the development of CAD. 
 
The aims of the study were  
 
2.1. to evaluate the heritability of EAT quantity - for this reason a classical twin 
study was performed and genetic and environmental influences on EAT 
volumes were estimated; in addition, a special attention was paid to evaluating 
heritability of EAT in comparison to that of abdominal SAT and VAT 
volumes; 
 
2.2. to assess the relationship of EAT volume to the presence of CAD - for this 
reason the association between EAT quantity and radiomorphological signs of 






3. Methods      
 




The study was conducted as a part of the BUDAPEST-GLOBAL (Burden of 
atherosclerotic plaques study in twins - Genetic Loci and the Burden of Atherosclerotic 
Lesions) clinical study; the participants had been co-enrolled with the large, international, 
multicenter Genetic Loci and the Burden of Atherosclerotic Lesions (GLOBAL) clinical 
study (http//:www.ClinicalTrials.gov: NCT01738828) (134, 135). 
 
The primary aim of the BUDAPEST-GLOBAL clinical study was to evaluate the 
influence of genetic and environmental factors on the burden of coronary artery disease. 
We hypothesized that the correlation of coronary plaque volume would be stronger 
between the MZ twins as compared to DZ twins, which might suggest that this CAD 
phenotype could be mainly driven by genetic factors. The secondary aims of the study 
were to quantify the heritability of coronary artery geometry, furthermore to assess the 
association between CAD heritability and the heritability of hepatic lipid accumulation, 
epicardial and abdominal adipose tissue quantity, carotid intima-media thickness and 
hemodynamic parameters. Classical and new cardiovascular risk factors were measured 
and potential associations with coronary artery disease and adipose tissue compartments 
were analyzed. In this PhD work, results of measurements of EAT and abdominal fat 
quantities and those of a clinical study performing to assess the potential association 
between EAT quantity and CAD are summarized.  
 
In the BUDAPEST-GLOBAL clinical study we searched the Hungarian Twin Registry's 
database (136) to identify adult MZ and same-sex DZ twins whose previously registered 
disease history meets the inclusion criteria of the study. The aim was to balance the 
overall participation for 50% females and at least 50% DZ twins. These twins were 
contacted by phone or email and the study protocols were described in detail. Thereafter, 




and exclusion criteria as well. The majority (90%) of the contacted twin pairs were willing 
to participate. Inclusion and exclusion criteria are listed in Table 3. Of note, subjects with 
pregnancy, regular alcohol consumption (more than 2 units daily), conditions possibly 
interfering with compliance during CT scanning and acute infection within three weeks 
were excluded from the study.  
 
Table 3. Enrollment criteria 
Inclusion criteria 
1. Monozygotic (MZ) twins and same-sex dizygotic (DZ) twins 
2. Age: females 40-75 years, males 35-75 years  
3. The participant has signed the institutional review board/ethics committee-
approved informed consent form 
Exclusion criteria 
1. Subjects for whom coronary computed tomography angiography is 
contraindicated per institutional standard of care (history of severe and/or 
anaphylactic contrast reaction, inability to cooperate with scan acquisition 
and/or breath-hold instructions, pregnancy, clinical instability, and renal 
insufficiency). 
2. Subjects with previous coronary arterial revascularization (percutaneous 
coronary intervention or coronary artery bypass grafting) 
3. Subjects with atrial fibrillation/flutter or frequent irregular or rapid heart 
rhythms, which occurred within the past 3 months 
4. Subjects with a pacemaker or implantable cardioverter-defibrillator implant 
5. Active congestive heart failure or the presence of known non-ischemic 
cardiomyopathy 
6. Known genetic disorders of atherosclerosis, lipid, or lipoprotein metabolism 
 
 
All subjects were asked not to smoke and not to eat three hours, not to drink alcohol and 
coffee ten hours prior to the examinations. During the enrolment, the zygosity was 
assessed using a standardized questionnaire based on seven self-reported responses (137). 





Table 4. Timeline of study procedures  
 Procedure Assessed parameters 





Past medical history and current lifestyle 
 Blood draw 
 
Laboratory parameters and panomics data 
 Non-contrast enhanced CT Agatston-score, epicardial fat, hepatic 
lipid accumulation, abdominal fat  
 Contrast-enhanced CT 
 
Coronary plaque and geometry  
Day 2 Echocardiography 
 
Standard analysis and speckle tracking 
 Vascular ultrasonography 
 
Both carotid and femoral arteries 
 Hemodynamic measurements Brachial and central blood pressures, 




In the BUDAPEST-GLOBAL study we enrolled prospectively a total of 202 twin 
subjects (101 twin pairs) between April 2013 and July 2014. We summarize the main 
clinical characteristics of the patients here in Table 5. As in some patients we recognized 
inadequate image quality for the respective analysis, the number of patients in a particular 
clinical study differed from that of the total cohort. Therefore, the patients’ characteristics 
of the specific clinical study are incorporated into the relevant results.  
 
The national ethics committee approved the BUDAPEST-GLOBAL study (ETT 
TUKEB: 58401/2012/EKU [828/PI/12]; Amendment: 12292/2013/EKU). All patients 
provided written, informed consent before the investigations. The study was carried out 






Table 5. Demographics, twin characteristics in the BUDAPEST-GLOBAL study 
* Data are mean values plus or minus standard deviation. 









Women (%) 130 (64.4%)   74 (60.7%) 56 (70.0%) 0.18 
Age (years)* 56.2 ± 9.4  54.9 ± 9.7 58.3 ± 8.4 0.01 
Height (cm)* 166.3 ± 9.6  166.2 ± 10.0 166.4 ± 9.0 0.87 
Weight (kg)* 77.3 ± 17.2  77.4 ± 17.7 77.1 ± 16.4 0.92 
Body mass index (kg × m-2)* 27.8 ± 5.3  27.8 ± 5.0 27.9 ± 5.8 0.94 
Waist circumference (cm)* 97.1 ± 14.0  96.8 ± 14.2 97.5 ± 13.7 0.72 
Hypertension (%) 86 (42.6%) 49 (40.2%) 37 (46.3%) 0.39 
Diabetes mellitus (%) 18 (8.9%) 12 (9.8%) 6 (7.5%) 0.57 
Dyslipidemia (%) 87 (43.1%) 48 (39.3%) 39 (48.8%) 0.19 




3.1.2. Anthropometric data and medical history 
 
Complete physical examination was performed and anthropometric parameters (weight, 
height and waist circumference) were recorded. Weight was measured with calibrated 
digital scale while height was recorded with a wall-mounted stadiometer. Body mass 
index (BMI - kg/m2) was calculated from weight and height values (weight [kg] was 
divided by height [m] on square meter). We measured waist circumference by a standard 
method at the midpoint between the lowest rib and the iliac crest at the end of expiration, 
placing the tape horizontally.  
Brachial blood pressure was measured prior the CT. A 12-lead ECG and 




Smoking habit was assessed and smoking years were recorded and alcohol consumption 
was evaluated as units per week. Physical activity, diet and socio-economic status were 
assessed by using questionnaires. Prevalence of hypertension, diabetes mellitus, 
dyslipidemia and cerebrovascular disease was documented based on the medical history 
of the participants.  
 
 
3.1.3. Laboratory parameters  
 
Enrolled twins underwent a peripheral blood draw, and blood was aliquoted and stored as 
whole blood, plasma, serum, and buffy coat. All subjects underwent whole genome 
sequencing according the protocol described in the GLOBAL study (134). This part of 
the study is still ongoing and does not belong to the current PhD work. Conventional 
biomarker testing was performed at Health Diagnostic Laboratory, Inc (Richmond, VA; 
United States of America). Fasting lipid profile was measured on an auto-analyzer using 
standard clinical methods (Beckman-Coulter). Hemoglobin A1c was measured using 
Trinity Biotech reagents (Trinity Biotech USA Inc, Jamestown, NY).  
 
 
3.1.4. Epicardial fat volumetric assessment 
 
Every subject underwent a non-contrast enhanced CT scan of the heart using a 256-slice 
CT scanner (Philips Brilliance iCT, Philips Healthcare, Best, The Netherlands; 120 kVp 
with tube current of 20 to 50 mAs depending on BMI, gantry rotation time 270 ms). The 
pericardial space was manually traced in each CT-slice in the native cardiac CT datasets. 
The adipose tissue was defined as tissue in the attenuation range of -45 to -195 HU. EAT 
was defined as any adipose tissue within the visceral pericardium from the level of the 
right pulmonary artery to the diaphragm (57, 113). The EAT segmentation was 
automatically interpolated within the manually traced region of interest (ROI), and the 
volume was calculated by using an offline workstation (Extended Brilliance Workspace, 
Philips Healthcare, Best, The Netherlands). Representative cases from the twin study can 






Figure 6. Epicardial adipose tissue (EAT) quantity  
Representative cases from the study: epicardial fat volume in a monozygotic twin pair. 
Volume rendered reconstructions are shown of the mediastinal region; epicardial fat 
volume is marked with yellow. 
 
 
3.1.5. Assessment of abdominal SAT and VAT 
 
Subsequently after the non-enhanced cardiac CT a single 5 mm thick slice (120 kVp; 200 
mA; gantry rotation time, 270 ms) was acquired at the level of L3-L4 vertebrae. The 
single CT slice was loaded onto an offline workstation and the subcutaneous adipose 
tissue (SAT) and visceral adipose tissue (VAT) areas (cm2) were measured using a 
dedicated offline workstation (Extended Brilliance Workspace, Philips Health Care, Best, 
The Netherlands). A semi-automated software tool identified the abdominal muscular 
wall separating the SAT and VAT compartments with the possibility of manual adjustment 
when needed. To identify pixels containing adipose tissue an attenuation range of -45 to 




Importantly, the native CT of the heart and abdomen resulted in a small (0.70 ± 0.16 mSv) 
radiation dose. 
Representative cases from the twin study can be seen in Figure 7. 
 
 
Figure 7. Abdominal subcutaneous and visceral adipose tissue compartments (SAT 
and VAT) in monozygotic twin pairs - representative cases from the study 
a-b) Axial images of the abdomen at the level of the L3/L4 vertebrae. Subcutaneous 
fat (orange color) is predominant in this monozygotic twin pair. 
c-d) Axial images of the abdomen at the level of the L3/L4 vertebrae. Visceral fat (blue 





3.1.6. Cardiac computed tomography    
 
ECG triggered coronary CT angiography (CTA) was performed using a 256-slice 
multidetector CT (Brilliance iCT, Philips Health Care, Best, The Netherlands). We 
administered per os β-blockers (metoprolol, maximum dose 100 mg) 1 hour before the 
CT scan if the heart rate was >65 beat per minute. Intravenous β-blocker (metoprolol) 
was administered (maximum cumulative dose 20 mg) on the table if the heart rate was 
still higher than 65 beat per minute. Sublingual nitroglycerin (0.8 mg) was administered 
on the table, maximum 2 minutes before the image acquisition. Images were acquired 
during a single inspiratory breath hold in axial mode with 270 ms rotation time, 
128×0.625 mm collimation, tube voltage of 100-120 kVp, maximum effective tube 
current-time product of 200-300 mAs at 78% of the R-R interval. Triphasic contrast 
injection protocol was used with 80 mL of iodinated contrast agent in average (Iomeprol 
400 g/cm3, Iomeron, Bracco Imaging S.p.A., Milano, Italy); mixture of contrast agent and 
saline (10 mL contrast agent and 30 mL saline); and 40 mL saline solution, all injected at 
a rate of 4.5-5.5 ml/s. We have reconstructed the minimum slice thickness (0.8 mm) 
available in prospective ECG triggered image acquisition with an increment of 0.4 mm, 
which resulted in an approximately 0.6 mm isotropic resolution. The mean effective 
radiation dose of the coronary CTA scans was 3.64±1.04 mSv (dose length product: 
260.1±74.5 mGy×cm). All image analyses were performed offline on dedicated cardiac 
workstations (Intellispace Portal, Philips Healthcare, Best, The Netherlands).  
 
 
3.1.7. Coronary plaque assessment  
 
The coronary CTA datasets were analyzed on a qualitative and quantitative basis. 
Coronary segments with a minimum diameter of 2.0 mm are included in the analysis. 
Each coronary segment is assessed for presence of plaque, plaque type, degree of stenosis, 
plaque features and plaque attenuation pattern. Coronary plaque is classified as non-
calcified plaque, partially calcified plaque or calcified plaque (139, 140). Stenosis is 
graded as none, minimal (<25%), mild (25%-49%), moderate (50%-69%), severe (70%-




Segment involvement score and segment involvement score index is used to provide a 
semi-quantitative measurement of plaque burden (141). In the clinical study for 
evaluating the relationship of EAT volume to the CAD, coronary CTA was evaluated on 
subject-to-subject basis and subjects were classified into groups with and without CAD 
(CAD-positive and CAD-negative subjects).  
 
 
3.1.8. Reproducibility of measuring EAT, SAT and VAT quantities 
 
For assessing the reproducibility of EAT, SAT and VAT quantity measurements, two 
readers (Adam L. Jermendy, Zsofia D. Drobni) performed repeated measurements on 10 
randomly selected MZ twin pairs and 10 randomly selected DZ twin pairs images in order 
to determine the intra-class correlation coefficient (ICC). 
 
 
3.1.9. Statistical analysis 
 
Continuous variables are expressed as mean ± standard deviation (SD), whereas 
categorical variables are expressed as numbers and percentages. MZ and DZ twins were 
compared using Student's t-tests and Chi-square tests. Correlations were calculated using 
Pearson correlation coefficients. Coefficient values are interpreted as: 1.00 - 0.81: 
excellent; 0.80 - 0.61: good; 0.60 - 0.41: moderate; 0.40 - 0.21: fair; 0.20 - 0.00: poor 
(142). Descriptive statistics, correlations and reproducibility measurements were 
calculated using IBM SPSS Statistics version 23 (IBM, Armonk, NY, USA). 
Heritability was assessed in two steps; first, co-twin correlations between the siblings 
were analyzed in MZ and DZ pairs separately. Next, genetic structural equation models 
were used to model the magnitude of genetic and environmental factors influencing the 
different fat compartments.  
All phenotypes are caused by genetic and environmental factors. MZ twins share nearly 
100% of their genome, while DZ twins only share half. Genetic similarity is caused by 
additive genetic components (A). While MZ twins share almost 100% of A, DZ twins 




i.e. same early childhood, education in the same school, living in the same town, etc. 
which equally effect the siblings and unique factors (E) such as specific eating and 
drinking habits, different physical activity and life-style, etc. which cause differences 
within families. In our study, both MZ and DZ twins shared 100% of their C factors and 
none of their E factors. Covariance between the siblings can be decomposed into A, C 
and E latent variables using genetic structural equation models (143). The likelihood ratio 
test was used to assess the fit of submodels compared to the full model. If the fit did not 
decrease significantly by removing one of the parameters, then the more parsimonious 
submodel was selected. Furthermore, multivariate genetic models can be used to further 
decompose the results of the heritability estimates into common and unique genetic and 
environmental factors. Common genetic factors refer to genes that are driving the 
heritability of all three fat components simultaneously (Ac), while common (Cc) and 
unique (Ec) environmental factors refer to circumstantial factors that affect the heritability 
of all three phenotypes. The remaining variance then can be attributed to genetic (As), 
common (Cs) and unique (Es) environmental factors specific of a given phenotype, which 
are independent of the other phenotypes. Therefore, the heritability of the fat 
compartments was decomposed to common (Ac, Cc, Ec) and specific (As, Cs, Es) genetic 
and environmental factors. Independent and common pathway models were used to find 
the most parsimonious model best describing our data. All calculations were adjusted for 
age and sex. Log likelihood-based 95% confidence intervals (CI) were calculated for all 
estimated parameters. All calculations were performed using R version 3.2.5. (144). Twin 
modelling was performed using OpenMx version 2.5.2 (145). A p value lower than 0.05 
was considered significant. 
 
 
3.2. Assessing the relationship of EAT volume to CAD  
 
3.2.1. Patients and methods 
 
We included 195 subjects (age: 56.1±9.4 years, female 64.1%) from the BUDAPEST-
GLOBAL study. All subjects underwent coronary CT angiography (CTA) and were 




respectively), based on the presence or absence of any plaque in coronary CTA. In 
addition, we measured the EAT volume on a native cardiac scan and the abdominal 
adipose tissue areas on a single CT-slice acquired at the L3/L4 level. Details of methods 
are given in the previous sections. 
 
 
3.2.2. Statistical analysis 
 
We used Student’s unpaired t-test for assessing the statistical difference between CAD-
pos and CAD-neg groups and a robust maximum likelihood estimation for correcting the 
potential bias from set of twins. We estimated the association between CAD and risk 
factors (including EAT, SAT and VAT values) using a logistic regression analysis. We 
used female gender, age, hypertension, dyslipidemia, diabetes mellitus, BMI, EAT, SAT 






4.1. Assessing genetic and environmental influences on EAT quantity 
in comparison to abdominal SAT and VAT volumes  
 
Overall, 180 twins (57 MZ twin pairs, 33 DZ twin pairs) were included from the 
BUDAPEST-GLOBAL study. Our study population represents a middle-aged, slightly 
overweight Caucasian population (Table 6).  
Intra-reader agreement showed excellent reproducibility for all CT based fat 
measurements as intra-class correlations (ICC) proved to be higher than 0.98 (ICCEAT = 
0.99; ICCSAT = 0.98; ICCVAT = 0.99). We also found excellent reproducibility regarding 
inter-reader variability (ICCEAT = 0.98; ICCSAT = 0.99; ICCVAT = 0.99). 
Co-twin correlations between the siblings showed that for all three parameters, MZ twins 
have stronger correlations than DZ twins, suggesting prominent genetic effects (EAT: rMZ 
= 0.81, rDZ = 0.32; SAT: rMZ = 0.80, rDZ = 0.68; VAT: rMZ = 0.79, rDZ = 0.48). 
For all three fat compartments AE model excluding common environmental factors 
proved to be best fitting [EAT: A: 73% (95% CI = 56%-83%), E: 27% (95% CI = 16-
44%); SAT: A: 77% (95% CI = 64%-85%), E: 23% (95% CI = 15%-35%); VAT: A: 56%  
(95% CI = 35%-71%), E: 44% (95% CI = 29%-65%)]. Detailed results can be found in 
Table 7. 
In multi-trait model fitting analysis overall contribution of genetic factors to EAT, SAT 
and VAT was 80%, 78% and 70%, whereas that of environmental factors was 20%, 22% 
and 30%, respectively (Table 8). We began with multi-trait model fitting by running a 
Cholesky decomposition of our data (Model 1, Cholesky ACE). All further models were 
compared to this full model. We dropped all C-s in the 2. model (Model 2, Cholesky AE) 
which did not decrease fit significantly (p = 0.85, AIC = 6.47) indicating the 
insignificance of common environmental factors, thus later models only assuming A and 
E factors were considered. Independent pathway model calculating with common and 




than model 2 (p = 0.85, AIC = 6.54). We calculated a common pathway model (Model 4, 
Common pathway AE 1) where common A and E factors were mediated through a latent 
phenotype, while the residual variance was decomposed to specific A and E factors which 
showed better fit based on information criteria measures (p = 0.78, AIC = 4.57). A model 
similar to the previous one (Model 5, Common pathway AE 2) but dropping the specific 
A of VAT proved to be the best fitting model (p = 0.85, AIC = 2.57). Detailed contribution 
of common and specific genetic and environmental factors for all three fat compartments 
can be found in Table 8, while the path diagram of the model can be found in Figure 8.  
 
Results of the multi-variate analysis suggest that a common latent phenotype is associated 
with the tissue compartments investigated. Based on our results, 98% (95% CI = 77%-
100%) of VAT heritability can be accounted by this common latent phenotype which also 
effects SAT and EAT heritability. This common latent phenotype accounts for 26% (95% 
CI = 13%-42%) of SAT and 49% (95% CI = 32%-72%) of EAT heritability. This 
common latent phenotype is influenced by genetics in 71% (95% CI = 54%-81%) and 
environmental effects in 29% (95% CI = 19%-46%). Accordingly, the proportion of 
common and specific genetic and environmental factors contributing to the adipose tissue 
quantities may differ from each other, for example in case of EAT heritability is caused 
by 35% common genetic, 45% specific genetic, 14% common environmental, and 6% 
specific environmental factors (Figure 8).  
 
We also assessed whether the heritability of one of the parameters was independent of 
the remaining two phenotypes. To answer these questions, we ran common pathway 
models where the EAT did not have any common factors to SAT and VAT (Model 6, 
Common pathway AE SAT-VAT), but this showed significantly decreased fit as 
compared to the full model (p = 5.61*10-26, AIC = 139.06). A model suggesting SAT was 
independent of VAT and EAT (Model 7, Common pathway AE VAT-EAT) also showed 
significantly decreased fit (p = 3.94*10-10, AIC = 60.53). The last model where we 
assumed VAT to be independent of SAT and EAT (Model 8, Common pathway AE SAT-
EAT) showed the worse fit (p = 2.17*10-32, AIC = 169.95). These results all suggest that 




SAT or VAT phenotype is associated with the remaining two phenotypes. Detailed model 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 8. Proportion of common and specific genetic and environmental factors 
contributing to the phenotypic quantity of CT based fat measurements 
 
Variable Epicardial fat Subcutaneous fat Visceral fat 
Common genetic and environmental factors 
    genetic factors (AC) 35%  18% 70% 
    environmental factors (EC) 14%   8% 28% 
Specific genetic and environmental factors 
    genetic factors (AS) 45%  60%  0%  
    environmental factors (ES)   6%  14%  2%  
Overall contribution of genetic and environmental factors 
    genetic factors (A) 80% 78% 70% 






























































































































































































































































































































































































































































































































































































































































































































































































Figure 8. Proportion of phenotypic variance of CT-based fat measurements  
The image shows squared standardized path coefficients of best fitting model 5. The 
common pathway model calculating with only common genetic and environmental 
factors proved to be the best. Residual variances were decomposed to specific genetic and 
environmental factors. In case of VAT only specific environmental factors were 
considered. A: additive genetic factors; E: unique environmental factors; Ac: common 
additive genetic factor; As: specific additive genetic factor; Ec: common environmental 
factor; Es: specific environmental factor; EAT: epicardial adipose tissue; SAT: 





4.2. Evaluating the association between EAT volume and the presence 
of CAD 
 
The patients’ characteristics are given in Table 10. Subjects from the CAD-pos group 
were older, had a higher BMI, weight, waist circumference, EAT, abdominal SAT and 
VAT volumes than subjects from the CAD-neg group. The ratio of EAT/SAT and 
EAT/BMI were higher in CAD-pos vs. CAD-neg patients. There were less female in the 
CAD-pos group, and in this group the presence of hypertension, dyslipidemia and 
diabetes were more frequent. Considering the lipid and glucose levels, we observed a 






Table 10. Clinical characteristics and main laboratory findings in CAD-negative and 
CAD-positive patients   
Continuous variables are presented as mean ± SD, while categorical as n (%). 
BMI: body mass index; CAD: coronary artery disease; EAT: epicardial adipose tissue; 
SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue; LDL: low-density 
lipoprotein; HDL: high-density lipoprotein 






age (years) 51.9 ± 9.3 59.7 ± 8.0 <0.001 
women 70 (78.6%) 55 (51.9%) <0.001 
hypertension 20 (22.5%) 62 (58.5%) <0.001 





        26.4     ±     4.2 
        72.4     ±     13.5 
14 (13.2%) 
         28.8    ±    5.6 
         81.0    ±    18.5 
  0.046 
  0.015 
  0.002 
waist circumference (cm) 92.8 ± 11.2 100.4 ± 14.9 <0.001 
EAT (cm3) 73.9 ± 27.3 117.2 ± 46.8 <0.001 

































total cholesterol (mmol/l) 5.6 ± 1.0 5.5 ± 1.1   0.598 
triglycerides (mmol/l) 1.3 ± 0.9 1.7 ± 1.1   0.021 
LDL-cholesterol (mmol/l) 3.5 ± 1.0 3.5 ± 1.0   0.847 
HDL-cholesterol (mmol/l) 1.7 ± 0.3 1.6 ± 0.4   0.070 
fasting blood glucose (mmol/l) 5.2 ± 0.9 5.5 ± 1.6   0.056 
 
 
Age (odds ratio [OR]: 1.100 p<0.001), hypertension (OR: 3.265 p<0.05), female sex (OR: 
0.117 p<0.001) and the volume of EAT in 10 cm3 clusters (OR: 1.315 p=0.001) were 
independent predictors for CAD. A 10 cm3 increment in the volume of EAT increased the 
risk of CAD with 31%, independently from BMI values. Female sex was a protective 





Table 11. Association between CAD (coronary artery disease) and 
clinical/laboratory parameters (risk factors) - results of the logistic regression 
analysis 
BMI: body mass index; EAT: epicardial adipose tissue; SAT: subcutaneous adipose 





Variable Odds ratio p 







hypertension 3.265 0.029 
dyslipidemia 1.763 0.208 
diabetes mellitus 1.489 0.638 
EAT (10 cm3) 1.315 0.001 
SAT (cm2) 1.007 0.057 






5.1. Heritability of EAT volume 
 
In a classical twin study, we showed that EAT, SAT and VAT quantities can be measured 
reliably by CT. We demonstrated that genetics have substantial, while environmental 
factors have only a modest influence on EAT, SAT and VAT volumes. Furthermore, our 
findings show that common and specific genetic effects both play an important role in 
developing these phenotypes. None of the phenotypic appearance of EAT, SAT and VAT 
proved to be completely independent of the other two. To the best of our knowledge, this 
is the first clinical study to evaluate the genetic and environmental dependence of EAT 
quantity and assessed simultaneously the joint heritability of EAT, SAT and VAT in twin 
pairs. 
In the total cohort, SAT mean quantity was higher (217.9 mm2) than that of VAT  
(156.6 mm2), the ratio of the quantities was nearly similar to other observations in a 
different population (138). The mean volume of EAT (97.1 cm3) was in the range of 
middle-aged healthy subjects (146). It is of note, that SAT and VAT was planimetrically 
but EAT was volumetrically measured in our cohort. Importantly, there was no significant 
difference in the assessed fat volumes comparing MZ to DZ subjects. 
We used advanced statistical methods to decipher the ratio of genetic and environmental 
effects on EAT, SAT and VAT quantities. In addition to single trait analysis, we 
performed multi-trait models to explore the complex interactions of multiple quantitative 
traits. This method has been recently used to dissect genetic mechanisms underlying 
complex diseases such as obesity (147, 148). We demonstrated that common genetic 
effects predominated over common environmental influences on the latent phenotype 
(71% versus 29%). On the other hand, while the latent phenotype markedly influenced 
VAT (98%), its effect was minimal on SAT (26%) and its impact on EAT was 
intermediate (49%). Our results also suggest a stronger phenotypic relationship of VAT 
to EAT than VAT to SAT. Latent phenotype could be related to BMI, obesity or total fat 
depot but this was not specifically investigated in our analysis. Regarding the whole 




appearance of EAT, SAT and VAT quantities are driven by common and specific genetic 
and environmental factors (Figure 8, Table 8). Finally, in Model 6-8 analyses (Table 9) 
we found that none of the fat compartments’ heritability was independent of the other 
two. Taken together, an interplay between common and specific genetic effects and 
environmental influences may be hypothesized, but the magnitude of their relative impact 
on different adipose tissue compartments varies. 
We demonstrated a relatively strong genetic dependence of EAT, which has not been 
described previously. The genetic dependence of anthropometric parameters (weight, 
height, BMI) has been well documented in former twin studies (126, 149, 150). 
Heritability of different ectopic fat compartments (hepatic lipid accumulation) was also 
investigated in twins, and in this case environmental factors predominated over genetic 
influences (151). Hence, heritability of different adipose tissue compartments and that of 
ectopic fats may vary. 
The presence of strong genetic predisposition does not automatically translate to the 
development of clinical disease phenotype. Considering this fact, early and continuous 
preventive efforts should be implemented. In case of obesity, intervention should be 
initiated as early as possible and all modifiable risk factors should be addressed with diet, 
physical activity and behavioral interventions starting as early as preschool age (152, 
153). Importantly, weight loss and exercise training may reduce EAT and abdominal 
adipose tissue volumes in adult subjects with obesity (94, 95). 
In our study, abdominal SAT and VAT were planimetrically assessed using a single  
5 mm thick slice at the level of L3-L4 vertebrae. This method was chosen in order to 
minimize the radiation dose. Moreover, it was documented in the Framingham heart study 
that planimetric area based measurements of abdominal SAT and VAT are strongly 
associated with abdominal SAT and VAT volumes (154).  
 
Non-contrast enhanced CT scan was used to evaluate quantities of various fat 
compartments, although other non-invasive methods (echocardiography, magnetic 
resonance imaging [MRI]) have been used previously. Echocardiography has several 
disadvantages including poor reproducibility and high dependence of investigator’s 




in routine clinical practice as CT. Furthermore, it is more expensive and has poorer spatial 
resolution compared to CT (19). The CT-based volumetric measurements in our study 
were highly reproducible. In addition, it is important to note that to the best of our 
knowledge, our study represents the first investigation using CT phenotyping of fat 
compartments in twins. 
Our results have to be interpreted within the context of their limitations. The sample size 
was modest but comparable to that of other classical twin studies (155). The zygosity in 
our twin cohort was classified according to validated questionnaires. Nevertheless, this 
method is widely accepted in clinical studies (137). Our results were derived from a 
healthy twin Caucasian population; therefore, the generalizability of our findings is 
limited. There was a small albeit significant difference in age of MZ versus DZ pairs but 
in our genetic analyses all parameters were age- and gender-adjusted. Nevertheless, an 
over-estimation of heritability might occur if twin-twin correlations would decline with 
age in DZ pairs but regarding the mean age of MZ and DZ pairs, a substantial effect 
should not be considered in our study.  
The strengths of our study are worth mentioning. The study was performed at an 
institution with vast experience in cardiac CT imaging and in conducting twin studies. 
Furthermore, all CT scans were performed by the same trained investigators. The 
reliability of CT scan measurements proved to be excellent. The use of structural equation 
model for evaluating heritability was not restricted to univariate analysis only. The 
predominant genetic effect on EAT, SAT and VAT was demonstrated not only in single 
trait but in multi-trait analyses; the latter is considered a more robust method.  
Taken together, genetic factors have substantial influence, while environmental factors 
have only a modest impact on EAT volume, abdominal SAT and VAT quantities. There 
is a considerable amount of common genetic background influencing the quantities of all 







5.2. Relationship of EAT volume to the presence of CAD 
 
We found that the quantity of EAT is associated - among others - with the presence of 
CAD as a 10 cm3 increment in the volume of EAT increased the risk of CAD with 31%, 
independently from the BMI values. Importantly, we do not want to interpret this result 
as a causative relationship, but we feel that our results are in accordance with former 
publications suggesting that EAT may contribute to the pathomechanism of CAD. For 
example, Ishii et al in an early investigation observed that in patients with myocardial 
bridge syndrome coronary arteries covered only by myocardium did not exhibit signs of 
atherosclerosis, indicating that EAT might play an important role in developing coronary 
atherosclerosis (41). From the early publication of Mazurek et al it became widely 
accepted that EAT - through vasocrine and paracrine mechanisms - might contribute to 
the pathomechanism of CAD (42). Furthermore, as we pointed out in the introduction 
(1.1.5. section), several cross-sectional studies, like ours, documented an association 
between EAT quantity and the presence of CAD. Obviously, from cross-sectional studies, 
either smaller or larger ones, one cannot conclude to causality. Notably, numbers of 
prospective clinical studies in this field are limited but follow-up observations published 
so far supported the causative relationship of  EAT volume to the presence of CAD (56, 
76).  
 
At the moment, EAT is not used in cardiovascular risk assessment models. Nevertheless,  
in the Heinz Nixdorf Recall Study Mahabadi et al documented that EAT volume has a 
predictive value on major adverse cardiovascular events (HR: 1.15 [95% CI: 1.01–1.30]), 
and improved the combined predictive value of Framingham risk score and Ca-scoring 
(AUC=0.749 vs. 0.764; p=0.011) (156). In addition, Cheng et al found that adding 
pericardial fat volume (≥125 cm3) to Framingham risk score and calcium score (≥400 
Agatston score) resulted in a trend toward improved prediction compared to the latter two 
only (ROC analysis, area under curve 0.73 vs. 0.68; p=0.058) (76). Further studies are 
needed to assess whether adding EAT quantity to other risk factors may really improve 





The limitations of our study should be mentioned. The study design was cross-sectional 
and, therefore, we cannot infer causality. The patients were asymptomatic and had 
negative medical history from cardiological point of view. Therefore, the generalizability 
of our results to other patients’ groups remains questionable. It is also of note that the 
morphological distinction of CAD-pos and CAD-neg cases may differ from that of 
clinical judgement.  
 
Taken together, our results are in line with former observations documenting that EAT 
quantity are associated with the presence of CAD and suggesting that EAT may have a 
role in the development of atherosclerosis in the coronary arteries. If the causal 
relationship could definitively be proven, then, interventions (lifestyle-modification or 
using drugs) should be considered reasonable to initiate for reducing EAT volume which 









We demonstrated that genetic effects have substantial, while environmental factors have 
only a modest influence on EAT, SAT and VAT volumes. Our findings show that 
common and specific genetic effects both play an important role in developing these 
phenotypes. None of the phenotypic appearance of EAT, SAT and VAT proved to be 
completely independent of the other two. 
 
We documented a relatively strong genetic dependence of EAT, which has not been 
described previously. The genetic dependence of anthropometric parameters (weight, 
height, BMI) has been well documented in former studies. Heritability of different ectopic 
fat compartments (hepatic lipid accumulation) was also investigated previously, and in 
this case environmental factors predominated over genetic influences. Hence, heritability 
of different adipose tissue compartments and that of ectopic fats may vary. 
 
The presence of strong genetic predisposition does not automatically translate to the 
development of clinical disease phenotype. Considering this fact, early and continuous 
preventive efforts should be implemented. In case of obesity, intervention should be 
initiated as early as possible and all modifiable risk factors should be addressed with diet, 
physical activity and behavioral interventions starting even in childhood.  
 
We found that the quantity of EAT is associated - among others - with the presence of 
CAD. These results suggest a potential role of EAT in the development of atherosclerosis 
in the coronary arteries. Accordingly, it is reasonable to consider the quantity of EAT in 










7. Summary  
 
Various adipose tissue compartments play an important role in the development of 
cardiometabolic diseases. The quantity of different fat compartments is influenced by 
genetic and environmental factors. The epicardial fat is a unique fat compartment 
localized between the myocardial surface and the visceral layer of the pericardium. 
Epicardial adipose tissue (EAT) can be quantified by non-invasive cardiac imaging 
techniques such as cardiac CT. Recently, experimental and clinical studies suggested that 
EAT may have an impact on the development and progression of coronary 
atherosclerosis. After adopting a proper and reliable method for evaluating the quantity 
of EAT by using cardiac CT scan in our department, we designed a study to evaluate the 
heritability of EAT quantity in comparison to that of abdominal subcutaneous adipose 
tissue (SAT) and visceral adipose tissue (VAT) volumes. In addition, we assessed the 
relationship of EAT volume to the presence of coronary artery disease (CAD). 
 
We demonstrated in a classical twin study that genetics have substantial, while 
environmental factors have only a modest influence on EAT, SAT and VAT volumes. 
Our findings show that common and specific genetic effects both play an important role 
in developing these phenotypes. None of the phenotypic appearance of EAT, SAT and 
VAT proved to be completely independent of the other two. As presence of strong genetic 
predisposition does not automatically translate to the development of clinical disease 
phenotype, early and continuous preventive efforts should be implemented in order to 
prevent obesity. Intervention should be initiated as early as possible and all modifiable 
risk factors should be addressed with diet, physical activity and behavioral interventions 
starting even in the childhood. 
 
In our study, the quantity of EAT was associated with the presence of CAD supporting 
former concepts that EAT might have a role in the development of CAD. It seems 
reasonable to involve EAT quantity into cardiovascular risk assessment, but the validity 






A kardiometabolikus kórképek patomechanizmusában a különböző zsírszöveti 
kompartmentek jelentős szerepet kapnak. A zsírszöveti raktárak, illetve a zsírszövet 
mennyiségének kialakulását genetikai és környezeti tényezők határozzák meg. Az 
epicardialis zsírszövet (EAT: epicardial adipose tissue) sajátos lokalizációjú és szerepű 
zsírszöveti kompartment, amely a myocardium felszíne és a pericardium visceralis 
lemeze között helyezkedik el. Az epicardialis zsírszövet mennyisége nem-invazív módon, 
kardiológiai képalkotó módszerekkel, viszonylag könnyen és pontosan a szív CT-
vizsgálatával kvantifikálható. Újabb kísérletes és klinikai tanulmányok eredményei arra 
utalnak, hogy az epicardialis zsírszövet befolyással lehet a koronária-ateroszklerózis 
kialakulására és progressziójára. Vizsgálatunk során az EAT mennyiségének öröklődését 
vizsgáltuk, összefüggésben a hasi subcutan zsírszövet (SAT: subcutaneous adipose 
tissue) és visceralis zsírszövet (VAT: visceral adipose tissue) alakulásával. Továbbá, 
vizsgáltuk az EAT mennyisége és a koronária-betegség (CAD: coronary artery disease) 
radiomorfológiai jeleinek együttes előfordulását. 
   
Klasszikus ikervizsgálat során igazoltuk, hogy a genetikai tényezőknek meghatározó, a 
környezeti tényezőknek kevésbé jelentős szerepe van az EAT, SAT és VAT 
mennyiségének alakulásában. A zsírszöveti kompartmentek fenotípusát közös és 
specifikus genetikai tényezők határozzák meg. Az EAT, VAT és SAT öröklődése nem 
bizonyult egymástól teljesen függetlennek. A genetikai meghatározottságot figyelembe 
véve fontos, hogy az elhízás elleni prevenciós tevékenység - az egészséges táplálkozásra, 
a rendszeres sportolásra való nevelés - már korán, gyermekkorban megkezdődjön.  
  
Adataink szerint az EAT mennyisége összefüggést mutat a CAD jelenlétével, ez a 
megfigyelés erősíti azokat a korábbi elképzeléseket, amelyek szerint az EAT szerepet 
kaphat a CAD kialakulásában. Az EAT meghatározása és értékének kockázatbecslő 
rendszerekbe történő beépítése elősegítheti a kardiovaszkuláris kockázat pontosabb, 
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